Odds of mortality or discharge to hospice reduced for those receiving supplemental oxygen or mechanical ventilation and/or ECMO
Your search for supplemental oxygen returned 22 results
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
The approval was based on data from the phase 3 ACTT-2 and COV-BARRIER studies.
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
The sBLA is supported by data from 4 randomized, controlled studies that evaluated tocilizumab for the treatment of COVID-19 in more than 5500 hospitalized patients.
The update was based on data from the COV-BARRIER study.
Based on efficacy results from 2 phase 3 studies, Lilly has decided to discontinue development of baricitinib for lupus.